

ECAT FOUNDATION

External quality Control for Assays and Tests

With a focus on Thrombosis and Haemostasis

REPORT



SURVEY 2025-L2 Lupus Anticoagulant Labcode 1492

Copyright © 2025
ECAT Foundation

Date of Issue : 14-July-2025

Survey : 2025-L2

Report : Lupus Anticoagulant

Note:

In the Survey Manual 2025 detailed information is given regarding the ECAT external quality assessment programme, including the statistical evaluation and explanation of the report.

This Survey Manual 2025 should be considered as an integral part of this survey report.

Please notice the information regarding the homogeneity of samples used and the between-laboratory variation in the paragraph on the statistical evaluation of the Survey Manual.

General Information**Exclusion of results**

Results < [value] or > [value] are excluded from the statistical analysis. When other results (e.g. deviating results) are excluded from the statistical analysis, these results are placed between brackets.

Lupus Anticoagulant

When selecting the unit seconds; all results should be reported in seconds and not partly in ratios; e.g. the result for the ECAT sample, the result for normal plasma and the result for MRI.

Antiphospholipid Antibodies

Please be aware of the selection of the correct unit for the method group "IL Acustar / INOVA Quanta Flash". Since there is a difference in the order of magnitude between the results of the "IL Acustar / INOVA Quanta Flash" method group and the other methods, it is expressed in the report as CU/mL instead of U/mL.

Additional Information

More explanatory information about the Lupus Anticoagulant survey report, see our website:

<https://clotpedia.nl/docs/lupus-anticoagulants-webinar-2023/>

Complaints

Any complaints regarding this survey report should be reported to the ECAT before **September 23rd, 2025**. Complaints received after this date will not be taken into consideration.

This report is authorized by:

Dr. M.J. van Essen-Hollestelle
Programme Expert

Note: The current Survey Manual can be downloaded from the 'Participant Area' of the ECAT website. Login and select the option 'View Documents'.

ECAT Foundation

Director: Dr. P. Meijer
ECAT Office
P.O. Box 107
2250 AC Voorschoten, The Netherlands
phone +31 (0) 71 3030 910; fax + 31 (0) 71 3030 919
E-mail: info@ecat.nl
Website: www.ecat.nl
VAT number: NL802836872B01

Registration number with the Chamber of Commerce (KvK) Gouda : 41174102
General terms of delivery are applicable to all our services.


All rights reserved. No part of this report may be reproduced, stored in a retrieval system, or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from the ECAT Foundation.
Appendices are an integral part of the total report.

*External quality Control for Assays and Tests
With a focus on Thrombosis and Haemostasis*


Ratio Normal Plasma

	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	380	1.69	19.8	1.06 - 2.82	1	1.48	-0.60	1.17	-1.53		
Hyphen-Biomed Cephen LS	12	2.28	7.8	2.02 - 2.52							
Roche aPTT Lupus	5	1.43		1.16 - 1.60							
Siemens Actin FS	6	1.24		1.18 - 1.27							
Siemens Actin FSL	88	1.36	6.8	1.15 - 1.69	1			1.17	-2.06		
Siemens Pathromtin SL	22	1.52	13.1	1.27 - 2.08	1	1.48	-0.16				
Stago PTT Automate/STA PTT	15	1.54	6.4	1.28 - 1.74							
Stago PTT LA	87	1.97	9.9	1.44 - 2.82							
Stago Staclot LA	15	1.67	11.6	1.26 - 2.37							
Werfen APTT SP	52	1.89	10.1	1.06 - 2.24							
Werfen HemosIL SynthAsil	42	1.69	7.5	1.30 - 1.90							
Werfen MixCon	15	1.62	5.8	1.13 - 1.75							
dAPTT	10	1.81	20.0	1.09 - 2.18							
Stago PTT LA	7	1.90		1.83 - 2.18							
dRVVT	565	1.82	8.6	1.18 - 2.50	1					1.77	-0.33
Hyphen Biomed Hemoclot LA-S	8	2.31		2.02 - 2.44							
Precision Biologic LA check	5	2.07		1.84 - 2.44							
Roche Lupus S	10	1.93	11.7	1.70 - 2.23							
Siemens LA1 screen	226	1.85	8.2	1.18 - 2.47	1					1.77	-0.56
Stago DRVVT screen	80	1.77	7.4	1.48 - 2.20							
Technoclone LA Screen	6	1.94		1.66 - 2.21							
Werfen HemosIL dRVVT screen	223	1.79	7.8	1.28 - 2.50							
PT	8	1.16		1.13 - 1.29							
SCT	153	1.98	17.5	1.39 - 3.71							
Werfen SCT screen	152	1.98	17.4	1.39 - 3.12							


Assays



APTT






DRVVT



Lupus Anticoagulant
Screening

Ratio MRI	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	118	1.62	20.2	1.12 - 2.97	1	1.46	-0.52	1.12	-1.53		
Siemens Actin FSL	27	1.32	4.6	1.12 - 1.45	1			1.12	-3.28		
Siemens Pathromtin SL	17	1.50	6.4	1.21 - 2.53	1	1.46	-0.45				
Stago PTT Automate/STA PTT	7	1.58		1.39 - 1.64							
Stago PTT LA	20	1.94	13.1	1.63 - 2.67							
Werfen APTT SP	17	1.90	6.7	1.61 - 2.09							
Werfen HemosIL SynthAsil	9	1.72		1.49 - 1.88							
dRVVT	107	1.83	9.1	1.32 - 2.42	1					1.77	-0.38
Roche Lupus S	5	1.93		1.90 - 2.03							
Siemens LA1 screen	61	1.86	8.0	1.32 - 2.27	1					1.77	-0.64
Stago DRVVT screen	12	1.71	7.7	1.53 - 1.88							
Werfen HemosIL dRVVT screen	24	1.77	8.6	1.49 - 2.42							
SCT	13	1.87	17.1	1.51 - 2.42							
Werfen SCT screen	13	1.87	17.1	1.51 - 2.42							

Assays

APTT

DRVVT

Comments

Several participants selected the wrong unit, e.g. ratio while the result was likely to be in seconds or vice versa. Other participants reported their result for the ECAT plasma in seconds while the result for their reference plasma or the mean of the reference interval was reported as a ratio or vice versa. One participant reported a negative result for their reference plasma. In all these cases the ratio between the ECAT plasma and the laboratories own reference plasma and/or the mean of the reference interval could not be correctly calculated. Another participant reported a mixing screening result, which should not be reported for the screening parameter, but for the mixing screening parameter. Therefore all these results were excluded from the statistical analysis.

The vast majority of performed screening tests (99%) were classified as elevated.

In general, comparable results were observed for the ratio ECAT plasma over Normal Plasma and ratio ECAT plasma over Mean Reference Interval (MRI).



Lupus Anticoagulant

Mixing (screening)

Sample No	25.125		
Sample Details	Plasma positive for Lupus Anticoagulant (LA Ratio approx. 1.6)		
Prior Use	Prior Use: None		
Unit	Ratio		
Expiry Date	31-January-2027		
Homogeneity	0.0 %	Homogeneity Parameter	LA ratio
Number of Participants	638		
Number of Responders	427	Response Rate	67 %


Assay	Elevated	Not elevated	Borderline	No Classification
APTT	264	45	0	8
dAPTT	11	0	0	0
dPT	2	0	0	0
dRVVT	340	12	0	8
KCT	2	0	0	0
Other	0	0	0	0
PNP	0	0	0	0
PT	0	6	0	1
SCT	82	1	0	1

Assay	Your classification							
	Mixing 1		Mixing 2			Mixing 3		
		TS2	TS3					
APTT		Not elevated						
dAPTT								
dPT								
dRVVT			Elevated					
KCT								
Other								
PNP								
PT								
SCT								


Ratio Normal Plasma

	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	285	1.45	18.4	1.03 - 2.25	1			1.17	-1.05		
Hyphen-Biomed Cephen LS	10	1.87	7.8	1.68 - 2.08							
Siemens Actin FSL	61	1.21	5.1	1.09 - 1.38	1			1.17	-0.64		
Siemens Pathromtin SL	17	1.26	11.3	1.09 - 2.08							
Stago PTT Automate/STA PTT	14	1.31	4.3	1.13 - 1.65							
Stago PTT LA	78	1.62	10.1	1.36 - 2.25							
Werfen APTT SP	40	1.62	8.3	1.06 - 2.11							
Werfen HemosIL SynthAsil	35	1.36	10.8	1.13 - 1.81							
Werfen MixCon	9	1.69		1.03 - 1.82							
dAPTT	8	1.61		1.44 - 1.81							
Stago PTT LA	6	1.54		1.44 - 1.81							
dRVVT	334	1.43	7.3	1.02 - 2.03	1					1.39	-0.34
Roche Lupus S	7	1.27		1.12 - 1.56							
Siemens LA1 screen	158	1.42	7.0	1.03 - 2.03	1					1.39	-0.26
Stago DRVVT screen	50	1.38	6.1	1.23 - 1.83							
Werfen HemosIL dRVVT screen	106	1.46	6.6	1.02 - 1.88							
PT	6	1.05		0.96 - 1.07							
SCT	82	1.74	13.6	1.10 - 3.71							
Werfen SCT screen	81	1.73	13.4	1.10 - 2.57							


Assays



APTT



DRVVT




Lupus Anticoagulant


Mixing (screening)

Ratio MRI	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	78	1.39	20.0	1.00 - 3.27	1			1.12	-0.96		
Siemens Actin FSL	21	1.17	5.0	1.00 - 3.27	1			1.12	-0.86		
Siemens Pathromtin SL	13	1.34	28.6	1.00 - 2.53							
Stago PTT Automate/STA PTT	5	1.35		1.27 - 1.46							
Stago PTT LA	14	1.64	14.9	1.36 - 2.18							
Werfen APTT SP	11	1.62	4.4	1.49 - 2.00							
Werfen HemosIL SynthAsil	7	1.40		1.16 - 1.68							
dAPTT	5	1.53		1.09 - 1.70							
dRVVT	67	1.42	7.6	1.04 - 2.12							
Roche Lupus S	5	1.34		1.04 - 1.38							
Siemens LA1 screen	37	1.44	6.9	1.28 - 1.83							
Stago DRVVT screen	7	1.39		1.21 - 1.48							
Werfen HemosIL dRVVT screen	14	1.41	8.5	1.25 - 2.12							
SCT	9	1.61		1.33 - 2.13							
Werfen SCT screen	9	1.61		1.33 - 2.13							


Assays



APTT



DRVVT



Comments

Several participants selected the wrong unit, e.g. ratio while the result was likely to be in seconds. Other participants reported their result for the ECAT plasma in seconds while the result for their reference plasma or the mean of the reference interval was reported as a ratio. In all these cases the ratio between the ECAT plasma and the laboratories own reference plasma and/or the mean of the reference interval could not be correctly calculated. Therefore all these results were excluded from the statistical analysis.


The majority of performed mixing tests (> 92%) were classified as elevated. No relation was observed between the methods used and the classification submitted by the participants.

In general, comparable results were observed for the ratio ECAT plasma over Normal Plasma and ratio ECAT plasma over Mean Reference Interval (MRI).


Ratio Normal Plasma

	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	169	1.20	12.5	0.78 - 3.29							
Hyphen Biomed Cephen	7	1.29		1.16 - 1.35							
Precision Biologic CRYOcheck Hex LA Cor	5	1.30		1.27 - 3.29							
Siemens Actin FS	74	1.14	8.9	0.78 - 1.32							
Stago PTT LA	7	1.47		1.21 - 2.03							
Stago Staclot LA	29	1.26	17.5	0.92 - 2.13							
Werfen Hemosil SynthAFax	17	1.14	8.7	1.01 - 1.71							
Werfen MixCon	14	1.14	6.5	1.06 - 1.64							
dAPTT	5	1.31		1.03 - 1.60							
dRVVT	571	1.21	6.4	0.50 - 1.70	1					1.31	1.37
Hyphen Biomed Hemoclot LA-C	8	1.27		1.17 - 1.37							
Roche Lupus C	10	1.26	6.5	1.15 - 1.35							
Siemens LA2 confirmation	228	1.20	6.0	0.50 - 1.68	1					1.31	1.57
Stago DRVVT Confirm	77	1.18	4.4	0.98 - 1.70							
Technoclone LA Confirm	7	1.22		1.08 - 1.24							
Werfen Hemosil dRVVT confirm	231	1.22	6.8	0.72 - 1.62							
SCT	153	1.26	7.8	0.92 - 2.18							
Werfen Hemosil SCT confirm	153	1.26	7.8	0.92 - 2.18							


Assays



APTT



DRVVT




Lupus Anticoagulant


Confirmation

Ratio MRI	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	37	1.19	10.7	0.91 - 2.46							
Siemens Actin FS	23	1.16	6.1	1.01 - 1.27							
Stago Staclot LA	5	1.15		0.91 - 1.54							
dRVVT	105	1.26	8.7	0.49 - 1.51	1					1.44	1.71
Roche Lupus C	5	1.28		1.18 - 1.34							
Siemens LA2 confirmation	59	1.27	10.4	0.49 - 1.51	1					1.44	1.27
Stago DRVVT Confirm	12	1.17	6.9	0.99 - 1.26							
Werfen HemosIL dRVVT confirm	25	1.27	5.8	1.10 - 1.47							
SCT	13	1.24	7.6	1.11 - 1.36							
Werfen HemosIL SCT confirm	13	1.24	7.6	1.11 - 1.36							


Assays



APTT



DRVVT



Comments

Several participants selected the wrong unit, e.g. ratio while the result was likely to be in seconds or vice versa. Other participants reported their result for the ECAT plasma in seconds while the result for their reference plasma or the mean of the reference interval was reported as a ratio or vice versa. In all these cases the ratio between the ECAT plasma and the laboratories own reference plasma and/or the mean of the reference interval could not be correctly calculated. Several participants reported also a confirmation result in Delta Seconds. However the difference in clotting time between the screen and confirmation test (or reagent 1 and reagent 2) should be reported in the interpretation section. Another participant reported a mixing confirm result, which should not be reported for the confirmation parameter, but for the mixing confirm parameter. All these results were excluded from the statistical analysis.

The majority of performed confirmation tests (67%) were classified as elevated. No relation was observed between the methods used and the classification submitted by the participants.

In general, comparable results were observed for the ratio ECAT plasma over Normal Plasma and ratio ECAT plasma over Mean Reference Interval (MRI).

Lupus Anticoagulant
Mixing (confirm)


Sample No	25.125		
Sample Details	Plasma positive for Lupus Anticoagulant (LA Ratio approx. 1.6)		
Prior Use	Prior Use: None		
Unit	Ratio		
Expiry Date	31-January-2027		
Homogeneity	0.0 %	Homogeneity Parameter	LA ratio
Number of Participants	638		
Number of Responders	225	Response Rate	35 %

Assay	Elevated	Not elevated	Borderline	No Classification
APTT	29	38	0	4
dAPTT	9	0	0	1
dPT	0	1	0	0
dRVVT	81	129	0	9
PNP	1	0	0	0
SCT	17	30	0	2


Assay	Your classification								
	Mixing 1			Mixing 2			Mixing 3		
			TS3						
APTT									
dAPTT									
dPT									
dRVVT			Elevated						
PNP									
SCT									

Ratio Normal Plasma	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	61	1.14	11.3	0.96 - 1.75							
Siemens Actin FS	26	1.05	4.9	0.96 - 1.15							
Werfen Hemosil SynthAFax	5	1.15		1.08 - 1.71							
Werfen MixCon	8	1.12		1.08 - 1.48							
dAPTT	5	1.41		1.15 - 1.61							
dRVVT	203	1.09	4.9	0.68 - 1.82	1					1.15	1.21
Siemens LA2 confirmation	101	1.09	3.9	1.00 - 1.34	1					1.15	1.55
Stago DRVVT Confirm	23	1.08	4.5	1.03 - 1.45							
Werfen Hemosil dRVVT confirm	69	1.10	7.7	0.68 - 1.82							
SCT	47	1.14	7.8	0.73 - 1.52							
Werfen Hemosil SCT confirm	47	1.14	7.8	0.73 - 1.52							


Assays



APTT



DRVVT




Lupus Anticoagulant

Mixing (confirm)


Ratio MRI

	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	11	1.21	17.2	0.99 - 1.51							
Siemens Actin FS	6	1.09		0.99 - 1.19							
dRVVT	42	1.13	7.7	0.93 - 1.41							
Siemens LA2 confirmation	26	1.15	7.5	1.04 - 1.29							
Werfen HemosIL dRVVT confirm	11	1.10	6.4	1.01 - 1.41							
SCT	6	1.10		1.09 - 1.17							
Werfen HemosIL SCT confirm	6	1.10		1.09 - 1.17							

Assays



DRVVT



Comments




Several participants selected the wrong unit, e.g. ratio while the result was likely to be in seconds or vice versa. Other participants reported their result for the ECAT plasma in seconds while the result for their reference plasma or the mean of the reference interval was reported as a ratio or vice versa. In all these cases the ratio between the ECAT plasma and the laboratories own reference plasma and/or the mean of the reference interval could not be correctly calculated. All these results were excluded from the statistical analysis.

The majority of performed mixing confirmation tests (59%) were classified as not elevated.

In general, comparable results were observed for the ratio ECAT plasma over Normal Plasma and ratio ECAT plasma over Mean Reference Interval (MRI).

Lupus Anticoagulant
Interpretation
Delta Seconds

	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	87	21.92	57.7	4.80 - 49.30							
Precision Biologic CRYOcheck Hex LA Cor	7	39.00		31.00 - 47.00							
Siemens Actin FS	27	15.80	89.7	4.80 - 42.50							
Stago Staclot LA	35	21.73	40.9	11.00 - 39.60							
dRVVT	126	27.05	15.7	6.30 - 64.40							
Siemens LA2 confirmation	66	27.51	15.1	13.00 - 64.40							
Stago DRVVT Confirm	9	24.00		20.90 - 30.10							
Werfen HemosIL dRVVT confirm	44	27.36	15.9	6.30 - 43.50							
SCT	24	37.16	32.9	18.80 - 78.60							
Werfen HemosIL SCT confirm	24	37.16	32.9	18.80 - 78.60							

Assays

APTT

DRVVT

Comments

It is not clear whether all results submitted for Delta Seconds reflect in all cases the difference in clotting time between the screen and confirmation test (or reagent 1 and reagent 2).




Please submit for Delta Seconds only the value which is the difference in clotting time between the screen and confirmation test (or difference between reagent 1 and reagent 2).

The following participants reported deviating results which were excluded from the statistical analysis:

1340 : 1.6
1484 (panel 1) : 0.54
1484 (panel 2) : 0.56
9907117 (panel 1) : 1.23
9907117 (panel 2) : 1.53
66606872 : 1.1

Lupus Anticoagulant
Interpretation
Ratio Screen/Confirmation - Standard

	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	29	1.39	15.5	1.13 - 2.80							
Siemens Actin FS	16	1.28	11.1	1.13 - 2.80							
dRVVT	117	1.62	8.6	1.19 - 1.92	1					1.52	-0.70
Siemens LA2 confirmation	82	1.63	7.4	1.25 - 1.92	1					1.52	-0.91
Stago DRVVT Confirm	9	1.53		1.41 - 1.71							
Technoclone LA Confirm	5	1.71		1.40 - 1.84							
Werfen HemosIL dRVVT confirm	15	1.60	12.0	1.19 - 1.85							
SCT	7	1.61		1.52 - 1.95							
Werfen HemosIL SCT confirm	7	1.61		1.52 - 1.95							

Assays

APTT

DRVVT

Comments

Some participants did not indicate which type of ratio screen/confirmation they reported (standard ratio or normalised ratio). These results have been excluded from the statistical analysis. Don't forget to select the type of ratio in the next survey.

The average ratio screen / confirmation is in general in line with the expected LA ratio (approx. 1.6). For the assay type "APTT" the LA ratio is slightly lower compared to the other assay types.

The following participants reported deviating results which were excluded from the statistical analysis:

271 : 12.0
 296A (instr. 1) : 30
 296A (instr. 2) : 32.8
 66603860 : 17.1


Lupus Anticoagulant

Interpretation


Ratio Screen/Confirmation - Normalised

	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	97	1.37	16.9	1.00 - 2.28							
Siemens Actin FS	57	1.29	14.6	1.09 - 2.28							
Werfen Hemosil SynthAFax	14	1.48	9.1	1.30 - 1.78							
Werfen MixCon	10	1.46	3.6	1.39 - 1.53							
dRVVT	385	1.50	8.3	1.09 - 1.99							
Hyphen Biomed Hemoclot LA-C	7	1.80		1.47 - 1.99							
Roche Lupus C	9	1.51		1.40 - 1.78							
Siemens LA2 confirmation	120	1.54	8.0	1.09 - 1.84							
Stago DRVVT Confirm	58	1.49	6.9	1.28 - 1.75							
Werfen Hemosil dRVVT confirm	184	1.46	7.8	1.18 - 1.90							
SCT	129	1.56	14.7	1.16 - 2.27							
Werfen Hemosil SCT confirm	129	1.56	14.7	1.16 - 2.27							


Assays



APTT



DRVVT



Comments

Some participants did not indicate which type of ratio screen/confirmation they reported (standard ratio or normalised ratio). These results have been excluded from the statistical analysis. Don't forget to select the type of ratio in the next survey.

The average ratio screen / confirmation is in general in line with the expected LA ratio (approx. 1.6). For the assay type "APTT" the LA ratio is slightly lower compared to the other assay types.



A participant reported a mixing ratio Screen/Confirmation result, but only undiluted ratio results can be evaluated for this parameter and therefore this result was excluded from the statistical analysis.

The following participants reported deviating or incomplete results which were excluded from the statistical analysis:

1505 (panel 2): .43
4561 (instr. 2) : 14.5

Lupus Anticoagulant
Interpretation
Percentage Correction - Standard

	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	19	27.82	40.7	8.45 - 72.00							
Siemens Actin FS	9	19.00		8.45 - 39.70							
dRVVT	54	40.48	12.0	20.00 - 98.00							
Siemens LA2 confirmation	34	40.65	9.2	20.50 - 66.00							
Stago DRVVT Confirm	6	37.42		28.94 - 46.58							
Werfen HemosIL dRVVT confirm	10	42.75	27.9	20.00 - 98.00							
SCT	9	41.93		11.90 - 52.04							
Werfen HemosIL SCT confirm	9	41.93		11.90 - 52.04							

Assays

DRVVT

Comments

Some participants did not indicate which type of correction they have reported (standard correction or normalised correction). These results have been excluded from the statistical analysis. Don't forget to select the type of correction in the next survey.

Some participants reported a ratio instead of a percentage correction result and were excluded from the statistical analysis.


Lupus Anticoagulant

Interpretation


Percentage Correction - Normalised

	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	30	33.60	41.4	13.95 - 77.00							
Siemens Actin FS	14	29.15	51.4	13.95 - 56.10							
dRVVT	77	34.78	20.9	18.00 - 111.11							
Siemens LA2 confirmation	34	36.36	15.1	20.30 - 53.80							
Stago DRVVT Confirm	10	33.57	18.0	26.00 - 42.63							
Werfen HemosIL dRVVT confirm	31	33.67	29.3	18.00 - 111.11							
SCT	25	34.77	38.2	2.00 - 72.70							
Werfen HemosIL SCT confirm	25	34.77	38.2	2.00 - 72.70							


Assays



APTT



DRVVT



Comments

Some participants did not indicate which type of correction they have reported (standard correction or normalised correction). These results have been excluded from the statistical analysis. Don't forget to select the type of correction in the next survey.

Some participants reported a ratio instead of a percentage correction result and were excluded from the statistical analysis.

Lupus Anticoagulant

Final Conclusion

Testing Strategies	Classification				Your Classification			
	Equivocal	LA detected	LA not detected	No conclusion	Test System	Panel 1	Panel 2	Panel 3
Screen test only	2	13	0	5	1			
					2			
					3			
Screen and mixing test	3	70	2	14	1			
					2			
					3			
Screen and confirm test	8	445	9	4	1			
					2			
					3			
Screen, mixing and confirm test	3	286	13	3	1			LA detected
					2			
					3			
Screen, confirm, mixing test		164	10	1	1			
					2			
					3			
Mixing - confirmation	0	32	0	0	1			
					2			
					3			

Final Conclusion				Your Results		
Counts				Test System 1	Test System 2	Test System 3
LA detected	LA not detected	Equivocal	No Conclusion			
487	1	6	1	LA detected		

Comments

The sample used in this survey was plasma from a patient diagnosed with Lupus Anticoagulant (LA Ratio = approx. 1.6). No other types of inhibitors were present.


In total 494 participants gave a final conclusion. Of the participants who gave a final conclusion, approximately 99% classified the sample as positive. One percent classified the sample as equivocal. Thus, the vast majority of the participants correctly classified this sample as positive. A minority (0.2%) of the participants classified this sample as negative, this does not seem to be affected by the test strategy used by the participants.

Lupus Anticoagulant
AntiCardiolipin Antibodies IgG

Sample No	25.125		
Sample Details	Plasma positive for Lupus Anticoagulant (LA Ratio approx. 1.6)		
Prior Use	Prior Use: None		
Unit	GPL, U/mL, µg/mL, CU/mL		
Expiry Date	31-January-2027		
Homogeneity	0.0 %	Homogeneity Parameter	LA ratio
Number of Participants	638		
Number of Responders	236	Response Rate	37 %

Classification	Negative	Borderline	Low Positive	Medium Positive	High Positive	No Conclusion
Total	80	7	55	64	33	1

IgG	n	assigned value	CV (%)	range	Test System 1 Result	z-score	Test System 2 Result	z-score	Test System 3 Result	z-score
U/mL, µg/mL, GPL/MPL	146	12.2	45.7	1.2 - 160.0						
Aeskulisa Diagnostic GmbH	6	15.0		6.0 - 39.7						
Euroimmun	16	10.2	27.9	1.2 - 17.0						
Orgentec (Alegria)	17	18.6	15.0	11.5 - 26.5						
Orgentec (Elisa)	13	18.2	9.6	14.2 - 30.3						
Thermo Scientific ELiA	72	8.7	11.7	2.0 - 12.0						
Werfen INOVA Quanta Lite	5	12.5		10.3 - 12.9						
CU/mL	89	69.2	10.5	55.1 - 705.0						
Werfen Acustar / INOVA Quanta Flash	88	69.2	10.5	55.1 - 705.0						

GPL, U/mL, µg/mL

Comments

A positive classification has been observed by the majority of participants.


A heterogeneous pattern in the classification has been observed.

Lupus Anticoagulant
AntiCardiolipin Antibodies IgM

Sample No	25.125		
Sample Details	Plasma positive for Lupus Anticoagulant (LA Ratio approx. 1.6)		
Prior Use	Prior Use: None		
Unit	MPL, U/mL, µg/mL, CU/mL		
Expiry Date	31-January-2027		
Homogeneity	0.0 %	Homogeneity Parameter	LA ratio
Number of Participants	638		
Number of Responders	227	Response Rate	36 %

Classification	Negative	Borderline	Low Positive	Medium Positive	High Positive	No Conclusion
Total	228	1	1	0	0	1

IgG	n	assigned value	CV (%)	range	Test System 1 Result	z-score	Test System 2 Result	z-score	Test System 3 Result	z-score
U/mL, µg/mL, GPL/MPL	137	3.9	29.7	0.0 - 14.0						
Aeskulisa Diagnostic GmbH	6	2.2		1.0 - 10.3						
Biorad Bioplex	6	6.1		5.5 - 6.3						
Euroimmun	13	4.4	20.2	3.1 - 5.6						
Orgentec (Alegria)	17	3.8	15.3	3.1 - 5.4						
Orgentec (Elisa)	13	3.8	18.6	2.6 - 4.6						
Thermo Scientific EliA	66	3.5	21.2	2.3 - 7.2						
CU/mL	86	7.5	10.8	6.2 - 9.0						
Werfen Acustar / INOVA Quanta Flash	86	7.5	10.8	6.2 - 9.0						

MPL, U/mL, µg/mL

Comments

Most of the participants reported a negative classification.

The following participant reported a deviating result which was excluded from the statistical analysis:


1353: 0.38 U/mL

Lupus Anticoagulant
β2-Glycoprotein I Antibodies IgG

Sample No	25.125		
Sample Details	Plasma positive for Lupus Anticoagulant (LA Ratio approx. 1.6)		
Prior Use	Prior Use: None		
Unit	U, U/mL, µg/mL, CU/mL		
Expiry Date	31-January-2027		
Homogeneity	0.0 %	Homogeneity Parameter	LA ratio
Number of Participants	638		
Number of Responders	231	Response Rate	36 %

Classification	Negative	Borderline	Low Positive	Medium Positive	High Positive	No Conclusion
Total	23	11	72	40	87	1

IgG	n	assigned value	CV (%)	range	Test System 1 Result	z-score	Test System 2 Result	z-score	Test System 3 Result	z-score
U, U/mL, µg/mL	139	13.3	23.1	3.0 - 160.0	13.4	0.04				
Aeskulisa Diagnostic GmbH	6	9.8		3.0 - 14.4						
Euroimmun	14	13.8	17.7	10.7 - 17.9						
Orgentec (Alegria)	17	14.5	17.4	10.6 - 20.3						
Orgentec (Elisa)	13	15.6	26.3	10.6 - 28.4	13.4	-0.53				
Thermo Scientific ELIA	68	11.9	13.0	8.7 - 17.0						
Werfen INOVA Quanta Lite	7	23.0		18.8 - 32.5						
CU/mL	87	280.0	13.1	213.0 - 401.0						
Werfen Acustar / INOVA Quanta Flash	86	279.5	13.1	213.0 - 401.0						

U, U/mL, µg/mL

Comments

A positive classification has been observed by the majority of participants.

The following participant reported a deviating result which was excluded from the statistical analysis:


174 : 12 CU/mL

Lupus Anticoagulant
β2-Glycoprotein I Antibodies IgM

Sample No	25.125		
Sample Details	Plasma positive for Lupus Anticoagulant (LA Ratio approx. 1.6)		
Prior Use	Prior Use: None		
Unit	U, U/mL, µg/mL, CU/mL		
Expiry Date	31-January-2027		
Homogeneity	0.0 %	Homogeneity Parameter	LA ratio
Number of Participants	638		
Number of Responders	213	Response Rate	33 %

Classification	Negative	Borderline	Low Positive	Medium Positive	High Positive	No Conclusion
Total	210	5	1	0	0	0

IgG	n	assigned value	CV (%)	range	Test System 1 Result	z-score	Test System 2 Result	z-score	Test System 3 Result	z-score
U, U/mL, µg/mL	129	4.3	38.1	0.0 - 25.2	3.5	-0.47				
Aeskulisa Diagnostic GmbH	6	4.1		1.8 - 18.0						
Biorad Bioplex	6	10.1		8.6 - 10.8						
Euroimmun	13	17.4	11.0	13.0 - 25.2						
Orgentec (Alegria)	16	3.9	24.5	2.5 - 5.2						
Orgentec (Elisa)	13	4.1	19.9	3.0 - 5.0	3.5	-0.69				
Thermo Scientific EliA	60	3.4	20.8	0.0 - 5.5						
CU/mL	81	5.2	13.3	4.0 - 7.0						
Werfen Acustar / INOVA Quanta Flash	81	5.2	13.3	4.0 - 7.0						

U, U/mL, µg/mL

Comments

Most of the participants reported a negative classification.